Home > Dermatology > Psoriasis and PsA in transgender adults on hormone therapy

Psoriasis and PsA in transgender adults on hormone therapy

Presented By
Ms Julia Gao, Fenway Health, MA, USA
Conference
WPPAC 2021
Feminising gender-affirming hormone therapy in transgender adults may decrease the risk of psoriasis but not psoriatic arthritis (PsA). Masculinising gender-affirming hormone therapy had no significant impact on the risk of developing psoriasis or PsA. This was found in a retrospective comparative cohort study [1]. Transgender dermatologic literature is limited; no data exists on the prevalence and risk of psoriasis and PsA in the transgender/gender-diverse populations. Ms Julia Gao (Fenway Health, MA, USA) and colleagues conducted a retrospective comparative cohort study with electronic health records of transgender/gender-diverse adults on masculinising or feminising hormone therapy and cisgender adults seen at Fenway Health between 1 August 2014 and 1 August 2020. The sample of over 46,000 persons included approximately 1,400 adults on feminising hormone therapy, almost 1,600 adults on masculinising hormone therapy, over 25,000 c...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on